The CNPV program aims to reduce drug review times to 1-2 months, raising concerns about safety and regulatory scrutiny. Critics argue that accelerated timelines may lead to safety issues and strain ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback